PI Industries (PIIND) investor relations material

Executive summary

• Q1 FY27 revenue was INR 17,023 million, with EBITDA at INR 3,693 million and PAT ranging from INR 2,002 million to INR 2,442 million, reflecting mixed year-over-year trends.

• Domestic business saw 12% volume growth and over 50% growth in biologicals, while export and PI Health Sciences segments faced headwinds.

• Three new molecules were commercialized, and a new peptide-based biological product was launched in the US.

• Strategic investments continued in pharma, electronics, and specialty chemicals, with early positive signs in pharma CRDMO and new product launches in the pipeline.

• The business is transitioning back to a growth trajectory despite cyclical headwinds and global disruptions.

Financial highlights

• Q1 FY27 consolidated revenue: INR 17,023 million; EBITDA: INR 3,693 million (22% margin); PAT: INR 2,002–2,442 million.

• Gross margin: 57%; domestic agri business delivered 12% volume and 3% revenue growth year-over-year.

• Biologicals posted over 50% growth with a three-year CAGR of 15%.

• Export business saw an 8–12% volume/value decline, despite rupee depreciation.

• Net cash balance rose to INR 37,939–38,000 million; net working capital reduced by 19 days.

Outlook and guidance

• FY27 expected to outperform FY26, with export recovery in H2, new product launches, and pharma/biologicals scale-up.

• Revenue growth guidance maintained at low single digits, subject to industry cycles.

• ETR for FY27 expected around 24%.

• Five or more new products to be launched in FY27, supporting growth.

• Focus on sustaining gross margins through product mix optimization and agility amid volatility.